Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
Adenocarcinoma
/ drug therapy
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ genetics
Colonic Neoplasms
/ drug therapy
Follow-Up Studies
Humans
International Agencies
Microsatellite Instability
Mutation
Neoplasm Recurrence, Local
/ drug therapy
Neoplasm Staging
Proto-Oncogene Proteins B-raf
/ genetics
Survival Rate
ras Proteins
/ genetics
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
02
03
2019
pubmed:
19
6
2019
medline:
13
2
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain unclear. The objective of the study was to assess recurrence patterns according to microsatellite instability (MSI), RAS and BRAF All stage III CC patients from the PETACC-8 randomized trial tested for MSI, RAS and BRAF A total of 1650 patients were included. Recurrence occurred in 434 patients (26.3%). Microsatellite stable (MSS) patients had a significantly higher recurrence rate (27.2% vs. 18.7%, P = 0.02) with a trend to more pulmonary recurrence (28.8% vs. 12.9%, P = 0.06) when compared to MSI patients. MSI patients experienced more regional lymph nodes compared to MSS (12.9% vs. 4%, P = 0.046). In the MSS population, the recurrence rate was significantly higher in RAS (32.2%) or BRAF (32.3%) patients when compared to double wild-type patients (19.9%) (p < 0.001); no preferential site of recurrence was observed according to RAS and BRAF Microsatellite, RAS and BRAF
Sections du résumé
BACKGROUND
BACKGROUND
Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain unclear. The objective of the study was to assess recurrence patterns according to microsatellite instability (MSI), RAS and BRAF
METHODS
METHODS
All stage III CC patients from the PETACC-8 randomized trial tested for MSI, RAS and BRAF
RESULTS
RESULTS
A total of 1650 patients were included. Recurrence occurred in 434 patients (26.3%). Microsatellite stable (MSS) patients had a significantly higher recurrence rate (27.2% vs. 18.7%, P = 0.02) with a trend to more pulmonary recurrence (28.8% vs. 12.9%, P = 0.06) when compared to MSI patients. MSI patients experienced more regional lymph nodes compared to MSS (12.9% vs. 4%, P = 0.046). In the MSS population, the recurrence rate was significantly higher in RAS (32.2%) or BRAF (32.3%) patients when compared to double wild-type patients (19.9%) (p < 0.001); no preferential site of recurrence was observed according to RAS and BRAF
CONCLUSIONS
CONCLUSIONS
Microsatellite, RAS and BRAF
Identifiants
pubmed: 31209667
doi: 10.1245/s10434-019-07513-6
pii: 10.1245/s10434-019-07513-6
doi:
Substances chimiques
Biomarkers, Tumor
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
ras Proteins
EC 3.6.5.2
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM